

**Literaturverzeichnis zum Titelthema „Neu in der Hals-, Nasen- und Ohrenheilkunde“
von Privatdozent Dr. Benedikt Hofauer, Privatdozent Dr. Adam M. Chaker,
Professorin Dr. Barbara Wollenberg und Professor Dr. Clemens Heiser
Bayerisches Ärzteblatt 10/2022, Seite 480 ff.**

1. Dietz A, Stohr M, Zebralla V, Pirlich M, Wichmann G, Wiegand S. [Immuno oncology treatment in head and neck cancer]. *Laryngorhinootologie*. 2021;100(4):303-21.
2. Wiegand S, Wichmann G, Dietz A. Checkpoint-Inhibitoren - neuer Standard der Erst- und Zweitlinientherapie bei Kopf-Hals-Karzinomen. *Trillium Krebsmedizin*. 2021;30(3):191-7.
3. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2016;375(19):1856-67.
4. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet*. 2019;393(10167):156-67.
5. Burtneß B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet*. 2019;394(10212):1915-28.
6. Cohen EEW, Bell RB, Bifulco CB, Burtneß B, Gillison ML, Harrington KJ, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). *J Immunother Cancer*. 2019;7(1):184.
7. Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population--a review on the epidemiology of sleep apnea. *J Thorac Dis*. 2015;7(8):1311-22.
8. Eastwood PR, Barnes M, MacKay SG, Wheatley JR, Hillman DR, Nguyen XL, et al. Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea. *Eur Respir J*. 2020;55(1).
9. Heiser C, Steffen A, Hofauer B, Mehra R, Strollo PJ, Jr., Vanderveken OM, et al. Effect of Upper Airway Stimulation in Patients with Obstructive Sleep Apnea (EFFECT): A Randomized Controlled Crossover Trial. *J Clin Med*. 2021;10(13).
10. Heiser C, de Vries N. Upper Airway Stimulation in Obstructive Sleep Apnea: Best Practices in Evaluation and Surgical Management 1st ed. 2022 Edition ed: Springer; 2022.
11. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe--an underestimated disease. A GA(2)LEN study. *Allergy*. 2011;66(9):1216-23.
12. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology*. 2020;58(Suppl S29):1-464.

13. Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. *Allergy*. 2019;74(1):28-39.
14. Chaker AM. [Biologics in Rhinology - Forthcoming Personalized Concepts: the Future Starts Today]. *Laryngorhinootologie*. 2018;97(S 01):S142-S84.
15. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394(10209):1638-50.
16. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J Allergy Clin Immunol*. 2020;146(3):595-605.
17. Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. *J Allergy Clin Immunol*. 2022;149(5):1711-21 e6.
18. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021;9(10):1141-53.